Amylyx Pharmaceuticals (AMLX) Return on Assets (2022 - 2026)

Amylyx Pharmaceuticals' Return on Assets history runs 5 years deep, the most recent figure standing at 0.01% for Q1 2026.

• On a quarterly basis, Return on Assets changed 0.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
• Return on Assets retreated to 0.01% in Q1 2026 per AMLX's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Assets topped out at 0.0% in Q4 2023 and bottomed at 0.01% in Q4 2024.
• The 5-year median for Return on Assets is 0.01% (2025), against an average of 0.01%.
• Across the five-year window, Return on Assets climbed 1 bps in 2023 and declined 1 bps in 2024, its largest moves.
• Year by year, Return on Assets stood at 0.01% in 2022, then surged by 114 bps to 0.0% in 2023, then tumbled by 1219 bps to 0.01% in 2024, then surged by 61 bps to 0.0% in 2025, then plunged by 53 bps to 0.01% in 2026.
• Per Business Quant, the three latest AMLX Return on Assets figures stand at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).